AIIMS Delhi develops mobile apps to deal with mental illness

New Delhi: The All India Institute of Medical Sciences (AIIMS) in Delhi has developed two mobile apps for patients suffering from chronic mental illness and their caretakers.

As the whole world is reeling under the Covid-19 pandemic, cases of anxiety and depression have gone up.

AIIMS has developed two mobile apps to deal with severe mental illness for patients suffering from chronic mental illness and for those who got the first episode of such symptoms. The two apps – ‘Shaksham’ and ‘Disha’ – are for both who undergoes first such episode of symptoms and for those having severe mental illness.

Mamta Sood, senior psychiatrist at AIIMS, told IANS, “We have developed two mobile apps — Shaksham and Disha — to deal with mental illness.”

She added that the Shaksham app is for those suffering from chronic mental illness, while the Disha app will benefit persons who undergo first such episode of symptoms.

Both the apps have been developed in collaboration with the computer science departments of Indraprastha Institute of Technology, Delhi, and the University of Warwick, UK. The project was funded by the National Institute of Health Research, UK.

“The apps will be available for free public use from January next year. We are more concerned about the patient data to be used in the apps and once the data restoration is secured, we will launch it by January next year,” Sood said.

“The apps will also send reminder to the care givers for medicines and other requirements of the patients,” she added.

Asked about the mental problems faced by people during the ongoing pandemic, Sood said that an AIIMS research conducted on healthcare workers has revealed that 50 per cent of the healthcare workforce are facing symptoms like anxiety, depression and stress.

However, she added that having such symptoms and having the disease are different, as symptoms do not affect the patients, while disease affects all.

  • Related Posts

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch